A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France [0.03%]
法国接受食管癌或胃食管交界处癌手术患者的纳武单抗辅助治疗成本效益分析
Paul Casabianca,Marc Massetti,François-Emery Cotte et al.
Paul Casabianca et al.
Introduction: Esophageal and gastroesophageal junction cancer (EC/GEJC) is a poor prognosis disease with a high risk of recurrence even in patients curatively resected. Adjuvant nivolumab is currently used for patients wi...
Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy [0.03%]
Correction: 开发杜氏肌营养不良的自然史模型
Jonathan Broomfield,M Hill,F Chandler et al.
Jonathan Broomfield et al.
Published Erratum
PharmacoEconomics - open. 2024 Jul;8(4):643. DOI:10.1007/s41669-024-00506-6 2024
Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians [0.03%]
法国临床医生参与的鼓励使用阿达利姆单抗类似药的两项金融激励措施比较研究
Marion Tano,Pascal Paubel,Matthieu Ribault et al.
Marion Tano et al.
Background: In 2018, the French government introduced two mutually exclusive financial incentives to increase etanercept and insulin glargine biosimilar use. The general case redirects 20% of the price difference between ...
A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England [0.03%]
英格兰COVID-19远程居家监测服务的成本评估
Sonila M Tomini,Efthalia Massou,Nadia E Crellin et al.
Sonila M Tomini et al.
Background: Remote home monitoring services emerged as critical components of health care delivery from NHS England during the COVID-19 pandemic, aiming to provide timely interventions and reduce health care system burden...
Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment [0.03%]
认知、疲劳和肢体功能障碍对多发性硬化症致残进展的成本和生活质量的影响超出EDSS评估范围
Jürgen Wasem,Yanic Heer,Eleni Karamasioti et al.
Jürgen Wasem et al.
Background and objective: Understanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world studies have associated increasing costs and worsening quality of life...
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers [0.03%]
一线达拉莫单抗治疗新诊断的、不适合移植的多发性骨髓瘤：针对医疗支付者的成本效用分析和风险分析模型
Diana Beatriz Bayani,Yihao Clement Lin,Chandramouli Nagarajan et al.
Diana Beatriz Bayani et al.
Background and objective: This study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatment of newly diagnosed, transplant-ineligible multiple myeloma in Singapore: (1) d...
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy [0.03%]
维多利珠单抗作为一线药物治疗意大利溃疡性结肠炎患者的经济效果对比阿达木单抗序贯疗法
Jonathan Salcedo,Daniel Hill-McManus,Chloë Hardern et al.
Jonathan Salcedo et al.
Background: Today, there are many treatment options available for the management of ulcerative colitis, creating challenges in selecting the most efficacious and cost-effective treatment sequences. Treatments in the anti-...
Correction: NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances [0.03%]
纠正：NICE的途径试点：在困难情况下追求良好决策
Dawn Lee,Darren Burns,Ed Wilson
Dawn Lee
Published Erratum
PharmacoEconomics - open. 2024 Jun 5. DOI:10.1007/s41669-024-00499-2 2024
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina [0.03%]
奥拉帕利联合贝伐单抗用于阿根廷卵巢癌维持治疗的预算影响分析
Carlos Rojas-Roque,Constanza Silvestrini,Fernando Argento et al.
Carlos Rojas-Roque et al.
Objectives: To perform a budget impact analysis (BIA) of introducing olaparib as maintenance therapy in women who have BRCA mutations (BRCAm) with platinum-sensitive recurrent ovarian cancer (PSROC) in combination with be...
Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France [0.03%]
四价脑膜炎球菌B疫苗在法国婴儿中的公共卫生影响和成本效益分析
Gérard de Pouvourville,Manon Breau-Brunel,Véronique Loncle-Provot et al.
Gérard de Pouvourville et al.
Background and objectives: In France, meningococcal serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease (IMD) in infants and young children. Our objective was to illustrate the impact of...